- Previous Close
24.50 - Open
24.90 - Bid --
- Ask 24.00 x --
- Day's Range
23.40 - 24.90 - 52 Week Range
22.50 - 51.00 - Volume
3,170 - Avg. Volume
5,245 - Market Cap (intraday)
137.228M - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
7.33 - EPS (TTM)
3.26 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company's project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases. Xlife Sciences AG also focuses on functional screening of antibodies by microfluidics-based technologies; and offers Neuromex, a screening instrument for the early-stage detection of neurodegenerative diseases. Xlife Sciences AG was founded in 2019 and is based in Zurich, Switzerland.
www.xlifesciences.chRecent News: XLS.SW
View MorePerformance Overview: XLS.SW
Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XLS.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XLS.SW
View MoreValuation Measures
Market Cap
140.67M
Enterprise Value
195.85M
Trailing P/E
7.52
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
181.65
Price/Book (mrq)
0.52
Enterprise Value/Revenue
197.77
Enterprise Value/EBITDA
7.18
Financial Highlights
Profitability and Income Statement
Profit Margin
2,144.50%
Return on Assets (ttm)
-2.36%
Return on Equity (ttm)
4.47%
Revenue (ttm)
990.27k
Net Income Avi to Common (ttm)
21.24M
Diluted EPS (ttm)
3.26
Balance Sheet and Cash Flow
Total Cash (mrq)
99.78k
Total Debt/Equity (mrq)
15.11%
Levered Free Cash Flow (ttm)
-9.73M